393 related articles for article (PubMed ID: 29757500)
21. Reliability and Role of Mutation-specific H3F3A (Histone 3-3) G34W Immunohistochemistry to Differentiate Giant Cell Tumor of Bone From its Clinicoradiologic and Histologic Mimics: An Institutional Study.
Pasricha S; Pruthi M; Jajodia A; Kumar A; Gupta G; Sharma A; Tiwari A; Rohela H; Durga G; Kamboj M; Koyyala VPB; Mehta A
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):36-41. PubMed ID: 34347625
[TBL] [Abstract][Full Text] [Related]
22. [Expression of H3.3 G34W mutant-specific antibody in giant cell tumors of bone and its diagnostic value].
Wang X; Wu N; Zhang RS; Wei X; Ji RH; Ma HH; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):116-121. PubMed ID: 32074722
[No Abstract] [Full Text] [Related]
23. Histologic Spectrum of Giant Cell Tumor (GCT) of Bone in Patients 18 Years of Age and Below: A Study of 63 Patients.
Al-Ibraheemi A; Inwards CY; Zreik RT; Wenger DE; Jenkins SM; Carter JM; Boland JM; Rose PS; Jin L; Oliveira AM; Fritchie KJ
Am J Surg Pathol; 2016 Dec; 40(12):1702-1712. PubMed ID: 27526293
[TBL] [Abstract][Full Text] [Related]
24. Anti-Histone H3.3 G34W antibody is a sensitive and highly specific immunohistochemistry marker for the diagnosis of Giant cell tumor of bone. A validation based on analysis of 198 cases from a single centre in India.
Kamble A; Hui M; Rao KN; Narayanan R; Reddy BR; Uppin SG; Chandrasekhar P
Indian J Pathol Microbiol; 2022; 65(3):617-629. PubMed ID: 35900490
[TBL] [Abstract][Full Text] [Related]
25. [Giant-cell tumor of bone in 2022].
Larousserie F; Audard V; Burns R; de Pinieux G
Ann Pathol; 2022 Apr; 42(3):214-226. PubMed ID: 35523609
[TBL] [Abstract][Full Text] [Related]
26. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics.
Presneau N; Baumhoer D; Behjati S; Pillay N; Tarpey P; Campbell PJ; Jundt G; Hamoudi R; Wedge DC; Loo PV; Hassan AB; Khatri B; Ye H; Tirabosco R; Amary MF; Flanagan AM
J Pathol Clin Res; 2015 Apr; 1(2):113-23. PubMed ID: 27499898
[TBL] [Abstract][Full Text] [Related]
28. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
Ratnagiri R; Uppin S
J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
[TBL] [Abstract][Full Text] [Related]
29. Significance of Histone H3.3 (G34W)-Mutant Protein in Pathological Diagnosis of Giant Cell Tumor of Bone.
Miskad UA; Syamsul F; Dahlan H; Sungowati NK; Achmad D; Johan MP
Asian Pac J Cancer Prev; 2023 May; 24(5):1737-1741. PubMed ID: 37247296
[TBL] [Abstract][Full Text] [Related]
30. Histone Mutations and Bone Cancers.
Taylor EL; Westendorf JJ
Adv Exp Med Biol; 2021; 1283():53-62. PubMed ID: 33155137
[TBL] [Abstract][Full Text] [Related]
31. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.
Shooshtarizadeh T; Rahimi M; Movahedinia S
Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669
[TBL] [Abstract][Full Text] [Related]
32. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.
Amary F; Berisha F; Ye H; Gupta M; Gutteridge A; Baumhoer D; Gibbons R; Tirabosco R; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2017 Aug; 41(8):1059-1068. PubMed ID: 28505000
[TBL] [Abstract][Full Text] [Related]
33. [The study of the value of H3F3A G34W immunohistochemical staining in the diagnosis of giant cell tumor of bone].
Bai YQ; Yang TT; Zhang HZ
Zhonghua Bing Li Xue Za Zhi; 2019 Jul; 48(7):531-536. PubMed ID: 31288308
[No Abstract] [Full Text] [Related]
34. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
35. Detection of H3F3A p.G35W and p.G35R in giant cell tumor of bone by Allele Specific Locked Nucleic Acid quantitative PCR (ASLNAqPCR).
Gamberi G; Morandi L; Benini S; Resca A; Cocchi S; Magagnoli G; Donati DM; Righi A; Gambarotti M
Pathol Res Pract; 2018 Jan; 214(1):89-94. PubMed ID: 29254795
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis of 36 cases of chondroblastomas: A single institutional experience.
Rekhi B; Ghate S; Shah A; Ramadwar M; Gulia A
Ann Diagn Pathol; 2020 Feb; 44():151440. PubMed ID: 31862519
[TBL] [Abstract][Full Text] [Related]
37. Chondroblastoma: An Update.
Chen W; DiFrancesco LM
Arch Pathol Lab Med; 2017 Jun; 141(6):867-871. PubMed ID: 28557595
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
[TBL] [Abstract][Full Text] [Related]
39. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.
Behjati S; Tarpey PS; Presneau N; Scheipl S; Pillay N; Van Loo P; Wedge DC; Cooke SL; Gundem G; Davies H; Nik-Zainal S; Martin S; McLaren S; Goodie V; Robinson B; Butler A; Teague JW; Halai D; Khatri B; Myklebost O; Baumhoer D; Jundt G; Hamoudi R; Tirabosco R; Amary MF; Futreal PA; Stratton MR; Campbell PJ; Flanagan AM
Nat Genet; 2013 Dec; 45(12):1479-82. PubMed ID: 24162739
[TBL] [Abstract][Full Text] [Related]
40. Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone.
Yoshida KI; Nakano Y; Honda-Kitahara M; Wakai S; Motoi T; Ogura K; Sano N; Shibata T; Okuma T; Iwata S; Kawai A; Ichimura K; Yoshida A
Mod Pathol; 2019 Dec; 32(12):1751-1761. PubMed ID: 31285528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
